Nanomedicines for parkinson disease: Current status and future perspective

International Journal of Pharma and Bio Sciences

Volumn 4, Issue 1, 2013, Pages 692-704

  Jayaraj, Richard L ^a   Chandramohan, Vivek ^b   Namasivayam, Elangovan ^a  

^a PERIYAR UNIVERSITY   (India)

^b SIDDAGANGA INSTITUTE OF TECHNOLOGY   (India)

Author keywords

Drug delivery; Nanomedicine; Nanosystems; Parkinson disease; Polymeric nanoparticles

Indexed keywords

CARBON NANOFIBER; CARBON NANOTUBE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; DOXORUBICIN; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; NANOCAPSULE; NANOGEL; NANOLIPOSOME; NANOMATERIAL; NANOMICELLE; NANOSPHERE; NANOSUSPENSION; NANOWIRE; UNCLASSIFIED DRUG;

ABLATION THERAPY; ARTICLE; BIOSENSOR; BLOOD BRAIN BARRIER; CHOREA; CONFUSION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG STABILITY; DRUG TARGETING; DRUG UPTAKE; DYSKINESIA; DYSTONIA; GENE THERAPY; GENETIC TRANSDUCTION; HALLUCINATION; HUMAN; MOLECULAR BIOLOGY; MONOTHERAPY; MOTOR DYSFUNCTION; NANOMEDICINE; NANOTECHNOLOGY; NEUROSURGERY; NONHUMAN; PALLIDOTOMY; PARKINSON DISEASE; PARTICLE SIZE; PSYCHOSIS; STEM CELL TRANSPLANTATION; SUSTAINED DRUG RELEASE; THALAMOTOMY; THERMODYNAMICS;

EID: 84879807233     PISSN: None     EISSN: 09756299     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Richard L. Jayaraj., D. John Ravindar., K. Manigandan., Pavan Kumar Padarthi., and ElangovanNamasivayam. An Overview of Parkinson's Disease and Oxidative Stress: Herbal Scenario. Neuropathological Diseases, 1: 95-122, (2012)
2. Olesen J., Leonardi M. The burden of brain diseases in Europe. Eur J Neurol, 10(5): 471-77, (2003)
3. Andlin-Sobocki P., Jönsson B., Wittchen HU., Olesen J. Cost of disorders of the brain in Europe. Eur J Neurol, 12(1):1-27, (2005)
4. Findley L., Aujla M., Bain PG., Baker M., Beech C., Bowman C., Holmes J., Kingdom WK., MacMahon DG., Peto V., Playfer JR. Direct economic impact of Parkinson's disease: a research survey in the United Kingdom. MovDisord, 18:1139-45 (2003)
5. Jain CK., Vishwanathan N. Parkinson's disease: a perilous magic of nature. Sci Res Essay, 2(7): 251-55 (2007)
6. Samii A., Nutt JG., Ransom BR. Parkinson's disease. Lancet, 29;363(9423):1783-93 (2004)
7. World Health Organization. Ageing and Health in the WHO South East Asia Region. World Health Report 1999; 3-4.
8. Rajan IS. Population ageing and health in India. Centre for Enquiry into Health and Allied Themes, Survey No. 2804 and 2805, Mumbai. 2006.
9. Stocchi F. Optimising levodopa therapy for the management of Parkinson's disease. J Neurol, 252:(IV) 43-48 (2005)
10. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 59(12): 1937-43 (2002)
11. Singh N., Pillay V., Choonara YE. Advances in the treatment of Parkinson's disease. ProgNeurobiol, 81(1): 29-44 (2007)
12. Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann N Y AcadSci, 991: 1-14 (2003)
13. Burchfield KJ. Thalamotomy for movement disorders. NeurosurgClin N Am, 6(1): 55-71 (1995)
14. Guridi J., Lozano AM. A brief history of pallidotomy. Neurosurgery, 41(5): 1169-80 (1997)
15. U.S. Department of Health and Human Services. FDA approves implanted brain stimulator to control tremors. Retrieved October 18, 2006.
16. Umemura A., Jaggi JL., Hurtig HI., Siderowf AD., Colcher A., Stern MB., Baltuch GH. Deep brain stimulation for movement disorders: morbidity and mortality in 109 patients. J Neurosurg, 98(4): 779-84 (2003)
17. Singh N., Pillay V., Choonara YE. Advances in the treatment of Parkinson's disease. ProgNeurobiol, 81(1):29-44 (2007)
18. Zhang SM., Hernan MA., Chen H., Spiegelman D., Willett WC., Ascherio A. Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology, 59:1161-69 (2002)
19. Olanow CW. Dietary vitamin E and Parkinson's disease: something to chew on. Lancet Neurol, 2(2): 74 (2003)
20. Modi G., Pillay V., Choonara YE. Advances in the treatment of neurodegenerative disorders employing nanotechnology. Ann N YAcadSci, 1184:154-172 (2010)
21. Modi G., Pillay V., Choonara YE., Ndesendo VM., du Toit LC., Naidoo D. Nanotechnological applications for the treatment of neurodegenerative disorders. ProgNeurobiol, 88(4):272-285 (2009)
22. Staples M. Microchips and controlledrelease drug reservoirs. WileyInterdiscip Rev NanomedNanobiotechnol, 2(4):400-417 (2010)
23. Linazasoro G. Potential applications of nanotechnologies to Parkinson's disease therapy. Parkinsonism RelatDisord, 14(5): 383-392 (2008)
24. James F. Leary. Nanotechnology: what is it and why is small so big? Can J Ophthalmol, 45:449-56 (2010)
25. Reynolds AD., Stone DK., Mosley RL., Gendelman HE. Nitrated a-synucleininduced alterations in microglial immunity are regulated by CD4+ T cell subsets. J. Immunol, 182(7):4137-4149 (2009)
26. Mosley RL., Benner EJ., Kadiu I. Neuroinflammation, oxidative stress and the pathogenesis of Parkinson's disease. Clin. Neurosci. Res, 6(5):261-281 (2006)
27. Markovic Z., Trajkovic V. Biomedical potential of the reactive oxygen species generation and quenching by fullerenes (C60). Biomaterials, 29(26):3561-3573 (2008)
28. Santos SG., Santana JV., Maia FF Jr. Adsorption of ascorbic acid on the C60 fullerene. J. Phys. Chem. B, 112(45):14267-14272 (2008)
29. Kolosnjaj J., Szwarc H., Moussa F. Toxicity studies of fullerenes and derivatives. Adv. Exp. Med. Biol, 620:168-180 (2007)
30. GirishModi., VinessPillay., and Yahya E. Choonara. Advances in the treatment of neurodegenerative disorders employing nanotechnology. Ann. N.Y. Acad. Sci, 1184 154-172 (2010)
31. VDI Technologiezentrum GmbH, Düsseldorf, Workshop: Nanotechnologiefür den Wirkstofftransport (Nanotechnology for Drug Delivery), 2004.
32. Muller RH. & Keck CM. Drug delivery to the brain-realization by novel drug carriers. J. Nanosci.Nanotechno,.4:471-483 (2004)
33. Behan N., Birkinshaw C & Clarke N. Poly nbutyl cyanoacrylate nanoparticles: a mechanistic study of polymerization and particle formation. Bioma,.22: 1335-1344 (2001)
34. Calvo, P., B. Gouritin, H. Chacun. Long circulating pegylatedpolycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm. Res, 18: 1157-1166 (2001)
35. Alyaudtin, RN., Reichel A., R. Lobenberg. Interaction of poly(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro. J.Drug Target, 9:209-221(2001)
36. Kreuter J., Ramge P, Petrov V. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm. Res,20: 409-416 (2003)
37. Hyuk IMS., Jeong U., Xia Y. Polymer hollow particles with controllable holes in their surfaces. Nat.Mater, 4:671-675 (2005)
38. Kreuter J. Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain. J. Nanosci. Nanotechnol, 4:484-488 (2004)
39. Kreuter J., Alyautdin R., Kharkevich D., Ivanov A. Passage of peptides through the blood-brain barrier with collodial polymer particles (nanoparticles). Brain Res, 674:171-174(1995)
40. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev, 47:65-81(2001)
41. Kreuter J., Shamenkov D., Petrov V. Apolipoprotein-mediated transport of nanoparticle bound drugs across the blood-brain barrier. J. DrugTarget, 10:317-325 (2002)
42. Bronich TK., Bontha S., Shlyakhtenko LS. Template-assisted synthesis of nanogels from pluronicmodifiedpoly(acrylic acid). J. Drug Targeting, 14:357-366 (2006)
43. Bontha S., Kabanov AV., Bronich TK. Polymer micelles with cross-linked ionic cores for delivery of anticancer drugs. J. Control. Rel, 114:163-174 (2006)
44. Vinogradov, SV., Zeman AD., Batrakova EV., Kabanov AV. Polyplexnanogel formulations for drug delivery of cytotoxic nucleoside analogs. J. Control. Rel,107:143-157 (2005)
45. Kumar, RM., Sameti M. Polymeric nanoparticles for drug and gene delivery. In Encyclopediaof Nanoscience& Nanotechnology. Nalwa, H.S., 1 Edn. American Scientific Publishers 19, (2003)
46. Friedrich I., Reichl S., Muller-Goymann CC. Drug release and permeation studies of nanosuspensions based on solidified reverse micellar solutions (SRMS). Int. J. Pharm, 305:167-175 (2005)
47. Kabanov AV., Gendelman HE. Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog. Polym. Sci, 32:1054-1082 (2007)
48. McKenzie JL., Waid MC., Shi R., Webster TJ. Decreased functions of astrocytes on carbon nanofiber materials. Biomat,25:1309-1317 (2004)
49. duToit LC., Pillay V, Choonara YE. Patenting of nanopharmaceuticals in drug delivery: No small issue. Recent Patents on Drug Deliv. Form, 1:131-142 (2007)
50. Nguyen HK., Lemieux P., Vinogradov SV. Evaluation of polyether-polyethyleneimine graft copolymers as gene transfer agents. Gene Ther, 7:126-138 (2000)
51. Harada-Shiba M., Yamauchi K, Harada A. Polyion complex micelles as vectors in gene therapypharmacokinetics and in vivo gene transfer. Gene Ther,9:407-414 (2002)
52. Oishi M., Hayashi H., Iijima M., Nagasaki Y. Endosomal release and intracellular delivery of anticancer drugs using pHsensitive pegylatednanogels. J.Mater. Chem, 17:3720-3725 (2007)
53. Shi N., Zhang W., Zhu C. Brain-specific expression of an exogenous gene after i.v. administration. Proc. Natl. Acad. Sci. USA, 98:12754-12759 (2001)
54. Voinea M., Simionescu M. Designing of 'intelligent' liposomes for efficient delivery of drugs. J. CellMol. Med, 6: 465-474 (2002)
55. Mora M., Sagristá ML., Trombetta D. Design and characterization of liposomes containing longchain N-acylpes for brain delivery: penetration of liposomes incorporating GM1 into the rat brain. Pharm.Res,19: 1430-1438 (2002)
56. Schmidt, J., Metselaar JM, Wauben MHM. Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain, 126:1895-1904 (2003)
57. Gosk S., Vermehren C., Storm G., Moos T. Targeting anti-transferrin receptor antibody (OX26) and OX26-conjugated liposomes to brain capillary endothelial cells using in situ perfusion. J. Cereb. BloodFlow Metab, 24:1193-1204 (2004)
58. Chekhonin, VP., Zhirkov YA, Gurina OI. Pegylatedimmunoliposomes directed against brain astrocytes. Drug Deliv, 12:1-6 (2005)
59. Simpkins JW., Bodor N. Brain-targeted delivery of dopamine using a redox-based chemical delivery system. Adv. Drug Deliv. Rev, 14:243-249 (1994)
60. Fiandaca MS., Forsayeth JR, Dickinson PJ., Bankiewicz KS. Image-guided convection-enhanced delivery platform in the treatment of neurological diseases. Neurother, 5:123-127(2008)
61. Neuwelt EA. Mechanisms of disease: the bloodbrain barrier. Neurosurg, 54:131-140 (2004)
62. Nowakowski GS., Witzig TE. Radioimmunotherapy for B-cell non- Hodgkin lymphoma. Clin.Adv. Hematol. Oncol, 4:225-231 (2006)
63. Bobo RH., Laske DW., Akbasak A. Convection-enhanced delivery of macromolecules in the brain. Proc. Natl. Acad. Sci. USA, 91:2076-2080 (1994)
64. Yurek, D. 2007. Nanoparticle gene therapy for Parkinson's disease. Nanotechwire.com. http://nanotechwire.com/news.asp?nid=4393&ntid=183&pg=8. Accessed on 2.20.2009.
65. Kaplitt, M.G. & M.J. During. 2008. Gene therapystudy shows safety and statistically significant improvement in Parkinson's disease. Biomed. http://www.biomedicine.org/biology-news/Gene-therapystudyshows-safety-an d-statisticallysignificant-improvement-in-Parkinsonsdisease-5440-1/. Accessed on 2.20.2009.
66. Nisbet DR., Crompton KE, Horne MK. Neural tissue engineering of the CNS using hydrogels. J. Biomed. Mat. Res. Part B: App. Biomat, 1:251-263 (2007)
67. Sarojini S, Rajasekar S And Koumaravelou K. Carbon Nanotubes: A New Weapon In Health Care Treatment. International Journal of Pharma and Bio Sciences, 1(4): 644-649 (2010)
68. Dipti K Patil, Minakshi V Janjale, Umesh L Chaudhary, Shrikant H Patail, Sunil R.Bavaskar, Arvind R.Umarkar. Nanomedicine And Cancer: A Comperhensive Review. International Journal of Pharma and Bio Sciences, 1(4): 560-566 (2011)
69. Lindvall O., Hagell P. Role of cell therapy in Parkinson's disease. Neurosurg. Focus, 13:e2(2002)